Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

Hartmut Döhner(Universität Ulm), Elihu H. Estey(Fred Hutch Cancer Center), David Grimwade(King's College London), Sergio Amadori(University of Rome Tor Vergata), Frederick R. Appelbaum(Fred Hutch Cancer Center), Thomas Büchner(University of Münster), Hervé Dombret(Assistance Publique – Hôpitaux de Paris), Benjamin L. Ebert(Brigham and Women's Hospital), Pierre Fenaux(Hôpital Saint-Louis), Richard A. Larson(University of Chicago), Ross L. Levine(Memorial Sloan Kettering Cancer Center), Francesco Lo‐Coco(University of Rome Tor Vergata), Tomoki Naoe(National Hospital Organization), Dietger Niederwieser(Leipzig University), Gert J. Ossenkoppele(Vrije Universiteit Amsterdam), Miguel Á. Sanz(Universitat de València), Jorge Sierra(Hospital de Sant Pau), Martin S. Tallman(Memorial Sloan Kettering Cancer Center), Hwei‐Fang Tien(National Taiwan University Hospital), Andrew H. Wei(The Alfred Hospital), Bob Löwenberg(Erasmus MC), Clara D. Bloomfield(The Ohio State University)
Blood
November 28, 2016
10.1182/blood-2016-08-733196
Cited by 5,851Open Access
Full Text

Abstract

The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults, published in 2010, has found broad acceptance by physicians and investigators caring for patients with AML. Recent advances, for example, in the discovery of the genomic landscape of the disease, in the development of assays for genetic testing and for detecting minimal residual disease (MRD), as well as in the development of novel antileukemic agents, prompted an international panel to provide updated evidence- and expert opinion-based recommendations. The recommendations include a revised version of the ELN genetic categories, a proposal for a response category based on MRD status, and criteria for progressive disease.

Related Papers

No related papers found

Powered by citation graph analysis